Actavis, which is at the centre of much merger talk, is to acquire Durata Therapeutics and its antibiotic Dalvance in a deal worth at least $675 millionn.
Actavis has offered $23 per share in cash, plus a contingent value rights element of up to $5 per share depending on how well Dalvance (dalbavancin) does. The intravenous antibiotic was approved by the US Food and Drug Administration in May for acute bacterial skin and skin structure infections and it is also being developed for additional indications, such as hospitalised community-acquired pneumonia and paediatric osteomyelitis.
Chief executive Brent Saunders said the acquisition of Durata “is a strong strategic fit that strengthens Actavis’ emerging infectious disease franchise and aligns with our stated goal to make smart, targeted investments”. He added that Dalvance complements the firm’s antibiotic Teflaro (ceftaroline fosamil) and a ceftazidine-avibactam combination, currently in late-stage development, which are intended for use in the in-patient setting.
Actavis has been reportedly in talks to buy Salix Pharmaceuticals and was rumoured to have had a $50 billion bid by Allergan turned down last month.
By Kevin Grogan
Source: Pharma Times
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
